Targeted drugs for colon cancer commonly used in clinical practice can be divided into the following categories: first, anti-angiogenic targeted drugs, represented by bevacizumab, ramolutumab, furoquitinib, etc., which can close the binding of human vascular endothelial growth factor receptor and ligand and inhibit the generation of tumor neovascularization, thus exerting anti-tumor effects. Second, small molecule kinase inhibitors, such as panitumumab, cetuximab, regorafenib, etc.. It mainly kills tumor cells by inhibiting the activity of tumor mutation gene kinases, such as epidermal growth factor receptor gene and platelet growth factor receptor gene. Thirdly, immune checkpoint inhibitors, including nabumab, epilimumab, pablizumab, etc. These monoclonal antibodies can activate human immune cells and enhance the anti-tumor activity of immune cells, thus killing cancer cells in the body.